Cargando…

Expression and prognostic significance of m6A‐related genes in TP53‐mutant non‐small‐cell lung cancer

BACKGROUND: TP53 is an important tumor suppressor gene on human 17th chromosome with its mutations more than 60% in tumor cells. Lung cancer is the highest incidence malignancy in men around the world. N‐6 methylase (m6A) is an enzyme that plays an important role in mRNA splicing, translation, and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Zhuochen, Wan, Junhu, Guo, Manman, Wang, Yangxia, Yang, Zhengwu, Zhou, Fuyou, Li, Zhuofang, Ming, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761469/ https://www.ncbi.nlm.nih.gov/pubmed/34812534 http://dx.doi.org/10.1002/jcla.24118

Ejemplares similares

Long non-coding RNA LINC01559 exerts oncogenic role via enhancing autophagy in lung adenocarcinoma
por: Zhao, Zhuochen, et al.
Publicado: (2021)

N‐6 methylation‐related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment
por: Zheng, Jian, et al.
Publicado: (2021)

Ferroptosis-associated circular RNAs: Opportunities and challenges in the diagnosis and treatment of cancer
por: Yang, Ruotong, et al.
Publicado: (2023)

TMEM44-AS1 promotes esophageal squamous cell carcinoma progression by regulating the IGF2BP2-GPX4 axis in modulating ferroptosis
por: Yang, Ruotong, et al.
Publicado: (2023)

Long non‐coding RNA HOXC‐AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression
por: Yang, Zhengwu, et al.
Publicado: (2022)

Prognostic significance of TP53 alterations in breast carcinoma.
por: Andersen, T. I., et al.
Publicado: (1993)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
por: Hwang, Hye Jung, et al.
Publicado: (2020)

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers
por: Zhang, Wensheng, et al.
Publicado: (2017)

Regulators of Oncogenic Mutant TP53 Gain of Function
por: Yamamoto, Satomi, et al.
Publicado: (2018)

Translational readthrough of nonsense mutant TP53 by mRNA incorporation of 5-Fluorouridine
por: Palomar-Siles, Mireia, et al.
Publicado: (2022)

Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers
por: Vu, Trung, et al.
Publicado: (2023)

The arsenal of TP53 mutants therapies: neoantigens and bispecific antibodies
por: Yang, Chang, et al.
Publicado: (2021)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53
por: Abrams, Stephen L., et al.
Publicado: (2022)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

Overexpression of RBBP6, Alone or Combined with Mutant TP53, Is Predictive of Poor Prognosis in Colon Cancer
por: Chen, Jian, et al.
Publicado: (2013)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

NEK2, a promising target in TP53 mutant cancer
por: Cusan, Martina, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
por: Kim, Jin-Ah, et al.
Publicado: (2023)

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
por: Lehmann, Brian David, et al.
Publicado: (2015)

Establishing an 8‐gene immune prognostic model based on TP53 status for lung adenocarcinoma
por: Wu, Guodong, et al.
Publicado: (2022)

Significance of TP53 and immune-related genes to prostate cancer
por: Huang, Hang, et al.
Publicado: (2021)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Preoperative Platelet to Albumin Ratio Predicts Outcome of Patients with Non-Small-Cell Lung Cancer
por: Guo, Manman, et al.
Publicado: (2020)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

TP53 Co-Mutation Status Association with Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
por: Le, Xiuning, et al.
Publicado: (2022)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Mutant TP53 interacts with BCAR1 to contribute to cancer cell invasion
por: Guo, Alvin Kunyao, et al.
Publicado: (2020)

Ascorbate Inhibits Proliferation and Promotes Myeloid Differentiation in TP53-Mutant Leukemia
por: Smith-Díaz, Carlos C., et al.
Publicado: (2021)

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

Impairment of rigidity sensing caused by mutant TP53 gain of function in osteosarcoma
por: Luo, Ming, et al.
Publicado: (2023)

Involvement of TP53 and TP16 expression in human papillomavirus-associated non-small cell lung cancer
por: Li, Ming, et al.
Publicado: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a6gv4438gfsqtnmt8a6l1bucsu